Explore
Validate
Learn
Immunocytochemistry
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [6]
- Comments [0]
- Validations
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- V2545 - Provider product page
- Provider
- NSJ Bioreagents
- Product name
- GnRH Receptor Antibody
- Antibody type
- Monoclonal
- Antigen
- A synthetic peptide aa 1-29 (MANSASPEQNQHCSAINNSIPLMQGNLPY) from the N-terminal of human GnRHR was used as the immunogen for the GnRH Receptor antibody.
- Description
- Protein G purified antibody
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antibody clone number
- A9E4
- Vial size
- 20 µg, 100 µg (with sodium azide), 100 µg (without sodium azide), 7 ml (prediluted for IHC use, if applicable)
- Storage
- Store the GnRH Receptor antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Submitted references Triple negative breast cancers express receptors for LHRH and are potential therapeutic targets for cytotoxic LHRH-analogs, AEZS 108 and AEZS 125.
Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.
Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.
Chorionic gonadotropin and its receptor are both expressed in human retina, possible implications in normal and pathological conditions.
GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.
Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
Seitz S, Buchholz S, Schally AV, Weber F, Klinkhammer-Schalke M, Inwald EC, Perez R, Rick FG, Szalontay L, Hohla F, Segerer S, Kwok CW, Ortmann O, Engel JB
BMC cancer 2014 Nov 19;14:847
BMC cancer 2014 Nov 19;14:847
Substantial expression of luteinizing hormone-releasing hormone (LHRH) receptor type I in human uveal melanoma.
Treszl A, Steiber Z, Schally AV, Block NL, Dezso B, Olah G, Rozsa B, Fodor K, Buglyo A, Gardi J, Berta A, Halmos G
Oncotarget 2013 Oct;4(10):1721-8
Oncotarget 2013 Oct;4(10):1721-8
Powerful inhibition of experimental human pancreatic cancers by receptor targeted cytotoxic LH-RH analog AEZS-108.
Szepeshazi K, Schally AV, Block NL, Halmos G, Nadji M, Szalontay L, Vidaurre I, Abi-Chaker A, Rick FG
Oncotarget 2013 May;4(5):751-60
Oncotarget 2013 May;4(5):751-60
Chorionic gonadotropin and its receptor are both expressed in human retina, possible implications in normal and pathological conditions.
Dukic-Stefanovic S, Walther J, Wosch S, Zimmermann G, Wiedemann P, Alexander H, Claudepierre T
PloS one 2012;7(12):e52567
PloS one 2012;7(12):e52567
GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.
Morgan K, Meyer C, Miller N, Sims AH, Cagnan I, Faratian D, Harrison DJ, Millar RP, Langdon SP
BMC cancer 2011 Nov 3;11:476
BMC cancer 2011 Nov 3;11:476
Receptors for luteinizing hormone-releasing hormone (LHRH) in benign prostatic hyperplasia (BPH) as potential molecular targets for therapy with LHRH antagonist cetrorelix.
Rozsa B, Nadji M, Schally AV, Dezso B, Flasko T, Toth G, Mile M, Block NL, Halmos G
The Prostate 2011 Apr;71(5):445-52
The Prostate 2011 Apr;71(5):445-52
No comments: Submit comment
Supportive validation
- Submitted by
- NSJ Bioreagents (provider)
- Main image
- Experimental details
- SDS-PAGE Analysis of Purified, BSA-Free GnRH Receptor Antibody (clone A9E4). Confirmation of Integrity and Purity of the Antibody.
